Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir/Velpatasvir Regimens in HCV GT3b Cirrhosis
NCT05467826Phase 4Unknown
- Sponsor
- Peking University People's Hospital
- Start
- Sep 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of sofosbuvir + velpatasvir + voxilaprevir in hepatitis C (HCV) (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: Sustained Virologic Response at 12 Weeks. Status: unknown.
02
Drugs
sofosbuvir + velpatasvir + voxilaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT05467826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05467826.